Akebia Reports Q1 2026 Earnings: Vafseo Revenue Rises While Auryxia Declines
In its first-quarter earnings report for 2026, Akebia (AKBA) reported a net loss of $9.1 million compared to a previous net income of $6.1 million. The company saw increased revenue from Vafseo with nearly 7,500 patients and over 1,000 prescribers at quarter-end.
Tickers: $AKBA
Topics: financials product_performance revenue